Research location
San Pedro Garza García
Nuevo León, Mexico
Advertisement
Research activity in San Pedro Garza García
Nuevo León, MexicoCureCurrent currently publishes aggregate city-level research activity for this location: 28 trials and 29 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in San Pedro Garza García
27 linked trials · page 1 of 1A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically SuppressedNCT07650916 · 2026-06-25 · 1 site observation
RECRUITING
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 DiabetesNCT07351058 · 2026-03-23 · 1 site observation
RECRUITING
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 DiabetesNCT07351045 · 2026-03-16 · 1 site observation
RECRUITING
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]NCT07099898 · 2025-08-11 · 1 site observation
RECRUITING
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)NCT06841354 · 2025-03-16 · 1 site observation
RECRUITING
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)NCT06393374 · 2024-06-24 · 2 site observations
RECRUITING
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)NCT06312176 · 2024-04-14 · 1 site observation
RECRUITING
Online Patient Navigation Program for Patients With Breast CancerNCT06597773 · 2025-09-21 · 1 site observation
WITHDRAWN
Iron Metabolism in ObesityNCT07157332 · 2025-09-15 · 1 site observation
NOT_YET_RECRUITING
Online Mindfulness-based Stress Reduction for Patients Receiving ChemotherapyNCT06534957 · 2025-09-02 · 1 site observation
COMPLETED
Integrative Group Program for Type 2 Diabetes Mellitus (T2DM)NCT05888454 · 2023-07-24 · 1 site observation
UNKNOWN
Cardiac Function and Biomarkers in Patients With Obesity and OverweightNCT07455630 · 2023-06-20 · 1 site observation
COMPLETED
Multicenter Study to Evaluate a Systematized Communication Model for Breast Cancer PatientsNCT05837533 · 2023-05-17 · 1 site observation
COMPLETED
Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions.NCT06124547 · 2023-01-16 · 1 site observation
COMPLETED
Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.NCT06124495 · 2023-01-13 · 1 site observation
COMPLETED
Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions.NCT06124573 · 2022-11-07 · 1 site observation
COMPLETED
Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.NCT06124560 · 2022-10-28 · 1 site observation
COMPLETED
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast CancerNCT04975308 · 2021-10-04 · 1 site observation
ACTIVE_NOT_RECRUITING
Randomized Study to Evaluate an Intervention Based on Mindfulness to Reduce Anxiety in Breast Cancer SurvivorsNCT05837169 · 2021-09-23 · 1 site observation
COMPLETED
Randomized and Multicenter Study to Evaluate a Customizable Support Breast Cancer MaterialNCT05798312 · 2021-05-21 · 1 site observation
COMPLETED
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)NCT04623775 · 2021-02-17 · 1 site observation
COMPLETED
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBCNCT03562637 · 2018-12-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Accuracy of Markerless Motion Capture Evaluation in Parkinson's Disease After DBSNCT03607721 · 2017-03-01 · 1 site observation
COMPLETED
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid TumorsNCT02715284 · 2016-03-07 · 1 site observation
ACTIVE_NOT_RECRUITING
Changes in Iron Absorption and Availability Before and After Weight Loss in Obese Pre-menopausal Women and Men.NCT01347905 · 2011-02-01 · 1 site observation
COMPLETED
The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes MellitusNCT00385697 · 2006-10-01 · 1 site observation
COMPLETED
Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)NCT00095238 · 2002-06-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.